SEC Form 4 · accession 0001127602-17-031275
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Martin
Officer — Executive Chairman · Director
Period of report
Nov 1, 2017
Accepted (ET)
Nov 3, 2017 · 7:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 1, 2017 | M | 73,333 | $21.575 | A | 3,070,099 | D | |
| Common StockF3 | Nov 1, 2017 | S | 65,856 | $75.079 | D | 3,004,243 | D | |
| Common StockF4 | Nov 1, 2017 | S | 7,477 | $75.6045 | D | 2,996,766 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $21.575 | Nov 1, 2017 | M | 73,333 | D | — | Jan 30, 2018 | Common Stock | 73,333 | 73,333 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $74.46 to $75.46. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $75.47 to $75.81. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.